Fig. 3
From: Development and validation of a risk prediction score for patients with nasopharyngeal carcinoma
Comparison of AUC among TNM stage, treatment, EBV DNA, and our model in 1-year overall survival (OS), 3-year OS, and 5-year OS in the primary cohort (A–C) and the validation cohort (D–F)